| The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy SL Cheong, S Federico, G Spalluto, KN Klotz, G Pastorin Drug discovery today 24 (9), 1769-1783, 2019 | 64 | 2019 |
| The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches SL Cheong, S Federico, G Venkatesan, AL Mandel, YM Shao, S Moro, ... Medicinal Research Reviews 33 (2), 235-335, 2013 | 61 | 2013 |
| Advances in computational techniques to study GPCR–ligand recognition A Ciancetta, D Sabbadin, S Federico, G Spalluto, S Moro Trends in pharmacological sciences 36 (12), 878-890, 2015 | 53 | 2015 |
| The Significance of 2-Furyl Ring Substitution with a 2-(para-substituted) Aryl Group in a New Series of Pyrazolo-triazolo-pyrimidines as Potent and Highly Selective hA3 … SL Cheong, A Dolzhenko, S Kachler, S Paoletta, S Federico, B Cacciari, ... Journal of Medicinal Chemistry 53 (8), 3361-3375, 2010 | 48 | 2010 |
| Fluorescent ligands for adenosine receptors E Kozma, PS Jayasekara, L Squarcialupi, S Paoletta, S Moro, S Federico, ... Bioorganic & medicinal chemistry letters 23 (1), 26-36, 2013 | 46 | 2013 |
| Synthesis and pharmacological characterization of a new series of 5, 7-disubstituted-[1, 2, 4] triazolo [1, 5-a][1, 3, 5] triazine derivatives as adenosine receptor antagonists … G Pastorin, S Federico, S Paoletta, M Corradino, F Cateni, B Cacciari, ... Bioorganic & medicinal chemistry 18 (7), 2524-2536, 2010 | 45 | 2010 |
| Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A2A Adenosine Receptor Antagonists with Improved Water … S Federico, S Paoletta, SL Cheong, G Pastorin, B Cacciari, S Stragliotto, ... Journal of medicinal chemistry 54 (3), 877-889, 2011 | 43 | 2011 |
| Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A2A Adenosine Receptor Antagonists with Improved Water … S Federico, S Paoletta, SL Cheong, G Pastorin, B Cacciari, S Stragliotto, ... Journal of medicinal chemistry 54 (3), 877-889, 2011 | 43 | 2011 |
| Novel fluorescent antagonist as a molecular probe in A3 adenosine receptor binding assays using flow cytometry E Kozma, TS Kumar, S Federico, K Phan, R Balasubramanian, ZG Gao, ... Biochemical Pharmacology 83 (11), 1552-1561, 2012 | 42 | 2012 |
| A Novel Conjugated Agent between Dopamine and an A2A Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach A Dalpiaz, B Cacciari, CB Vicentini, F Bortolotti, G Spalluto, S Federico, ... Molecular pharmaceutics 9 (3), 591-604, 2012 | 40 | 2012 |
| Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment YM Shao, X Ma, P Paira, A Tan, DR Herr, KL Lim, CH Ng, G Venkatesan, ... PloS one 13 (1), e0188212, 2018 | 35 | 2018 |
| Targeting protein kinase CK1δ with riluzole: could it be one of the possible missing bricks to interpret its effect in the treatment of ALS from a molecular point of view? M Bissaro, S Federico, V Salmaso, M Sturlese, G Spalluto, S Moro ChemMedChem 13 (24), 2601-2605, 2018 | 32 | 2018 |
| A Triazolotriazine‐Based Dual GSK‐3β/CK‐1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition S Redenti, I Marcovich, T De Vita, C Pérez, R De Zorzi, N Demitri, ... ChemMedChem 14 (3), 310-314, 2019 | 30 | 2019 |
| Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A2A … L Michielan, C Bolcato, S Federico, B Cacciari, M Bacilieri, KN Klotz, ... Bioorganic & medicinal chemistry 17 (14), 5259-5274, 2009 | 28 | 2009 |
| 5, 7-Disubstituted-[1, 2, 4] triazolo [1, 5-a][1, 3, 5] triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors S Federico, A Ciancetta, N Porta, S Redenti, G Pastorin, B Cacciari, ... European Journal of Medicinal Chemistry 108, 529-541, 2016 | 25 | 2016 |
| Scaffold Decoration at Positions 5 and 8 of 1,2,4-Triazolo[1,5-c]Pyrimidines to Explore the Antagonist Profiling on Adenosine Receptors: A Preliminary Structure … S Federico, A Ciancetta, N Porta, S Redenti, G Pastorin, B Cacciari, ... Journal of Medicinal Chemistry 57 (14), 6210-6225, 2014 | 23 | 2014 |
| Exploring potency and selectivity receptor antagonist profiles using a multilabel classification approach: the human adenosine receptors as a key study L Michielan, S Federico, L Terfloth, D Hristozov, B Cacciari, KN Klotz, ... Journal of chemical information and modeling 49 (12), 2820-2836, 2009 | 22 | 2009 |
| Synthetic versatility of β-alkoxyvinyl trichloromethyl ketones for obtaining [1, 2, 4] triazolo [1, 5-a] pyrimidines LA Souza, JM Santos, M Mittersteiner, VP Andrade, MM Lobo, FB Santos, ... Synthesis 50 (18), 3686-3695, 2018 | 21 | 2018 |
| Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands S Federico, G Spalluto Expert Opinion on Therapeutic Patents 22 (4), 369-390, 2012 | 21 | 2012 |
| Impact of protein–ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2A ligand binding kinetics G Deganutti, A Zhukov, F Deflorian, S Federico, G Spalluto, RM Cooke, ... In Silico Pharmacology 5, 1-13, 2017 | 20 | 2017 |
